Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Comparison of Clinical and Imaging Outcomes of Different Doses of Adipose-Derived Stromal Vascular Fraction Cell Treatment for Knee Osteoarthritis.

Tsubosaka M., Matsumoto T., Sobajima S., Matsushita T., Iwaguro H., Kuroda R.

Prospective Study with a reported sample of 60 on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Ankle Injury, published in Cell Transplant (2021) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Transplant (2021)
Country
United States
Reported sample size
60
Source database
PubMed
PMID
35392685
PMCID
PMC9003644
DOI
10.1177/09636897211067454
Citations
15

Abstract (original English)

Background: Favorable clinical outcomes of the intra-articular injection of adipose-derived stromal vascular fraction (SVF) cells for knee osteoarthritis (OA) have been reported. This study aimed to compare the short-term clinical and imaging outcomes of different doses of SVF cells for knee OA treatment. Methods: : This study included 60 patients with knee OA who underwent intra-articular injection of SVF cells. The follow-up period was at least 12 months. The envelope method was used to prospectively quasi-randomized the patients to undergo treatment with different doses of SVF cells. Thirty patients received an intra-articular injection of 2.5×10 7 SVF cells (low-dose group), and the remaining 30 patients received an intra-articular injection of 5.0×10 7 SVF cells (high-dose group). Clinical evaluations were performed for range of motion, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), visual analog scale (VAS) for pain, and the Knee injury and Osteoarthritis Outcome Score (KOOS). Imaging evaluations, which included the hip-knee-ankle angle and magnetic resonance imaging Osteoarthritis Knee Score (MOAKS) features (bone marrow lesions, cartilage defects, osteophytes, Hoffa’s synovitis, and effusion synovitis), were also performed. All clinical and imaging evaluations were performed preoperatively and 12 months postoperatively and compared between the g

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueHumansInjections, Intra-ArticularMagnetic Resonance ImagingMesenchymal Stem Cell TransplantationOsteoarthritis, KneePainStromal Vascular FractionSynovitisTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research